Pfizer Limited The Capital, 1802 / 1901, Plot No. C- 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051 Tel: +91 22 6693 2000 Fax: +91 22 26540274 February 3, 2016 The Corporate Relationship Dept. The Manager BSE Limited Listing Dept 1 Floor, P.J.Towers The National Stock Exchange of India Ltd. Dalal Street, Fort Exchange Plaza, 5"" Floor, Mumbai - 400 001 Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Dear Sirs, Sub: Unaudited financial results and Limited Review Report for the third quarter and nine months ended December 31, 2015. Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith unaudited financial results for the third quarter and nine months ended December 31, 2015, which were approved by the Board of Directors of the Company at its Meeting held today, that commenced at 2.00 p.m. and concluded at 6.30 p.m. Also please find enclosed the Limited Review Report by our Auditors, M/s. BS R & Co. LLP, in respect of the above results. Thanking you, Yours truly, For Pfizer Limited esishn Prajeet Nair Company Secretary Encl: A/a Cc: National Securities Depository Limited (NSDL) Central Depository Services (India) Limited (CDSL) ctus.india@pfizer.com @ wwwopfizerindia.comBSR&Co. LLP ‘Chartered Accountants ‘3h Fer, tata Exc Trdeghane +9122) 43485300 ‘ooo Wis Comeaund roe Soya) aanssne8 ENE fa Marg Motor Review report To the Board of Directors Pfizer Limited ‘We have reviewed the accompanying statement of unaudited financial resuls (the Statement) of Pfizer Limited (he Company”) for the period ended 31 December 2015. This statement isthe ‘responsibility of the Company’ Management and has been approved bythe Board of Directors in ‘their meting held on 3 February 2016, Our responsi Wo issue a repor on these financial Sfatements based on our review. \We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity sued by the Insite of Chartered Accountants of India. This standant requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material Imistatement. A review is Tinited primarily 10 ingites of company personnel and analytical procedures applied to financial data and thus provides less assurance than an aut. We have not performed an audit and accordingly, we donot express an audit opinion ‘Based on our review conduct as above, nothing has come to oursitention thal causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable accounting standards specified under section 133 ofthe Companies Act 2013, read with Role 7 of the Companies (Accounts) Roles, 2014 and other recognised accounting practices and policies has no disclosed te information required tobe disclosed in terms of Regulation 33 of the SEDI (Listing Obligations and Disclosure Requirements) Regulations, 2015 inchadng the manner in ‘which isto be disclosed, or that it contains any material misstatement For BSR& Co. LLP Chartered Accountants Fimn’s Registration No: 101248W/W-100022 ae Sadashiv Shetty Mumbai "Partner 3 Febnunry 2016 Membership No: 018648Pfizer Limited Tne Capel 180211903, Foto €-70 lec Bons al Compo ena fe Memb! 0 051 Teton 2286932000 Faxs#81 2226840274 eee 4 4 3 5 a : ‘one zenarssorcooests a contacts india@pizercom © ven phzerinciacomnotes: 1 ‘the above results were reviewed and reeommended by the Audit Committee, for approval bythe Board, at te meeting held on February 3, 2016 and were approved and taken on record at the recting of the Board of Directors ofthe Company held on that date 4. The finenclal resuits for the quarter and nine months ended December 32, 2015 have been “ubjected toa limited review by the statutory auditors ofthe Company. The limited review report ‘Joes not contain any qualifications. The lite review report wil be led with the Stock Exchanges Se wil sso be avaliable on the Companys website - wna. com. 4. Exceptional tems during the quarter ended September 30, 2015 consists of, (a) Income from render of leave rights at Exprest Tower, net of related expenses (b) Expenses incurred n relation cartropowed transfer of business undertaking atthe Thane plant. Exceptional tems forthe queresr wica'bccember 31, 2018 and year ended March 3, 2015 was in relation to voluntary retirement scheme / other related costs. 14. The Company/s stock ying at Chennai locaton had been affected dve to flods, The Company has ceeccted an amount of € B12 leks as recelabl towards the insurance claim and has curenty “hasosce the sald amount under the ead “Other Income” in the financial resus ‘5. The Company has only one segment which i Pharmaceuticals. Therefore disclosure rleting 0 {ogments i ot applicable and accordingly not made. «6. ures for previous quarters / period have been regrouped / restated where necessry. oat .seidhar February 3, 2016 executive Director